Why Clinical Trials Stop: The Role of Genetics
Razuvayevskaya, O.; Lopez, I.; Dunham, I.; Ochoa, D.
Show abstract
Many drug discovery projects are started, but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the freetext reasons for 28,842 clinical trials that stopped before their endpoints were met. We then evaluated these classes in the light of the underlying evidence for the therapeutic hypothesis and target properties. We show that trials are more likely to stop due to lack of efficacy in the absence of strong genetic evidence from human populations or genetically-modified animal models. Furthermore, trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is not selectively expressed. These results support the growing use of human genetics to evaluate targets for drug discovery programmes.
Matching journals
The top 13 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Pathway activation model for personalized prediction of drug synergy 92%
- Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning 90%
- The Proportion of Randomized Controlled Trials That Inform Clinical Practice: A Longitudinal Cohort Study of Trials Registered on ClinicalTrials.gov 90%
Similar papers in this journal
Similar papers in this journal
- Cancer patient survival can be accurately parameterized, revealing time-dependent therapeutic effects and doubling the precision of small trials 92%
- Community assessment of cancer drug combination screens identifies strategies for synergy prediction 92%
- A Platform for Oncogenomic Reporting and Interpretation 91%
Similar papers in this journal
- Machine learning guided association of adverse drug reactions with in vitro target-based pharmacology 92%
- Multi-ancestry omic Mendelian randomization revealing putative drug targets of COVID-19 severity 90%
- Genomic Insights for Personalized Care: Motivating At-Risk Individuals Toward Evidence-Based Health Practices 89%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.